GlaxoSmithKline plumbs the discovery field (again), betting up to $815M for the latest add-on to its oncology pipeline
Five years after Novartis stepped up with a sizable deal that gave them worldwide rights to Surface Oncology’s lead cancer drug, GlaxoSmithKline is coming in at the other end of the pipeline, snagging a preclinical natural killer drug designed to whip up a more effective attack on cancer cells.
Unlike a lot of the preclinical collaborations we’ve seen, GSK is also freighting this with a significant amount of cash: $85 million upfront plus $730 million in milestones. And they see this new addition to the oncology pipeline as a prime candidate for future combos — all the rage these days.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.